Descrizione

Cell line development is a major step for examining the efficiency of drug discovery, toxicity and in vitro testing. It reduces time, effort and cost, which minimises the chance of research drugs failing at the clinical trial stage. The global cell line development market is poised to grow by US$ 4.5 miliardi durante 2022-2028, procedendo a un CAGR di 11.7% durante il periodo di previsione, secondo la società di dati e analisi StrategyHelix.

Il rapporto fornisce dati aggiornati sulle dimensioni del mercato per il periodo 2018-2021 e previsione a 2028 covering key market aspects like sales value for cell line development. The global cell line development market is segmented on the basis of product, source, tipo, applicazione, e regione. Per prodotto, the global cell line development market has been segmented into equipment, media and reagents. In 2021, the media and reagents segment made up the largest share of revenue generated by the cell line development market. Based upon source, the global cell line development market is categorized into mammalian, non-mammalian. The mammalian segment was the largest contributor to the global cell line development market in 2021. In base al tipo, the global cell line development market has been segmented into continuous cell lines, hybridomas, primary cell lines, recombinant cell lines. Per applicazione, the global cell line development market has been segmented into bioproduction, drug discovery, tissue engineering, altri. Geograficamente, the global cell line development market is segmented into Asia Pacific, Europa, Nord America, Rest of the World (RoW).

The global cell line development market is highly competitive. The report also includes the profiles of leading companies such as BioFactura Inc., Corning Incorporated, Fujifilm Diosynth Biotechnologies, GE Healthcare, Horizon Discovery Group plc, LakePharma Inc. (Curia Global Inc.), Lonza Group AG, Merck KGaA, Rentschler Biopharma SE, Sartorius AG, Selexis SA (JSR Corporation), Thermo Fisher Scientific Inc., WuXi AppTec Co. Ltd.

Il rapporto è una risorsa inestimabile per le aziende e le organizzazioni attive in questo settore. It provides a cohesive picture of the cell line development market to help drive informed decision making for industry executives, decisori politici, accademico, e analisti.

Ambito del rapporto

Prodotto: equipment, media and reagents
Source: mammalian, non-mammalian
Tipo: continuous cell lines, hybridomas, primary cell lines, recombinant cell lines
Applicazione: bioproduction, drug discovery, tissue engineering, altri
Regione: Asia Pacifico, Europa, Nord America, Rest of the World (RoW)
Anni considerati: la presente relazione copre il periodo 2018 A 2028

Principali vantaggi per gli stakeholder

– Get a comprehensive picture of the global cell line development market
– Individuare i settori in crescita e le tendenze per gli investimenti

Sommario

Parte 1. introduzione
– Ambito dello studio
– Periodo di studio
– Ambito geografico
– Metodologia di ricerca
Parte 2. Cell line development market overview
Parte 3. Ripartizione del mercato per prodotto
– Equipment
– Media and reagents
Parte 4. Market breakdown by source
– Mammalian
– Non-mammalian
Parte 5. Market breakdown by type
– Continuous cell lines
– Hybridomas
– Primary cell lines
– Recombinant cell lines
Parte 6. Market breakdown by application
– Bioproduction
– Drug discovery
– Tissue engineering
– Altri
Parte 7. Market breakdown by region
– Asia Pacifico
– Europa
– Nord America
– Rest of the World (RoW)
Parte 8. Aziende chiave
– BioFactura, Inc.
– Corning Incorporated
– Fujifilm Diosynth Biotechnologies
– GE Healthcare
– Horizon Discovery Group plc
– LakePharma, Inc. (Curia Global, Inc.)
– Lonza Group AG
– Merck KGaA
– Rentschler Biopharma SE
– Sartorius AG
– Selexis SA (JSR Corporation)
– Thermo Fisher Scientific Inc.
– WuXi AppTec Co., Ltd.
Informazioni su StrategyHelix
Disclaimer